p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act
Doxorubicin (DOX) is a highly effective chemotherapeutic drug, but its long-term use can cause cardiotoxicity and drug resistance. Accumulating evidence demonstrates that p53 is directly involved in DOX toxicity and resistance. One of the primary causes for DOX resistance is the mutation or inactiva...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/15/10/2259 |
_version_ | 1797598818539143168 |
---|---|
author | Yuanfang Guo Yufeng Tang Guangping Lu Junlian Gu |
author_facet | Yuanfang Guo Yufeng Tang Guangping Lu Junlian Gu |
author_sort | Yuanfang Guo |
collection | DOAJ |
description | Doxorubicin (DOX) is a highly effective chemotherapeutic drug, but its long-term use can cause cardiotoxicity and drug resistance. Accumulating evidence demonstrates that p53 is directly involved in DOX toxicity and resistance. One of the primary causes for DOX resistance is the mutation or inactivation of p53. Moreover, because the non-specific activation of p53 caused by DOX can kill non-cancerous cells, p53 is a popular target for reducing toxicity. However, the reduction in DOX-induced cardiotoxicity (DIC) via p53 suppression is often at odds with the antitumor advantages of p53 reactivation. Therefore, in order to increase the effectiveness of DOX, there is an urgent need to explore p53-targeted anticancer strategies owing to the complex regulatory network and polymorphisms of the p53 gene. In this review, we summarize the role and potential mechanisms of p53 in DIC and resistance. Furthermore, we focus on the advances and challenges in applying dietary nutrients, natural products, and other pharmacological strategies to overcome DOX-induced chemoresistance and cardiotoxicity. Lastly, we present potential therapeutic strategies to address key issues in order to provide new ideas for increasing the clinical use of DOX and improving its anticancer benefits. |
first_indexed | 2024-03-11T03:26:05Z |
format | Article |
id | doaj.art-1043419f1aaa420d99658535dcfd1a4c |
institution | Directory Open Access Journal |
issn | 2072-6643 |
language | English |
last_indexed | 2024-03-11T03:26:05Z |
publishDate | 2023-05-01 |
publisher | MDPI AG |
record_format | Article |
series | Nutrients |
spelling | doaj.art-1043419f1aaa420d99658535dcfd1a4c2023-11-18T02:43:55ZengMDPI AGNutrients2072-66432023-05-011510225910.3390/nu15102259p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing ActYuanfang Guo0Yufeng Tang1Guangping Lu2Junlian Gu3School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, ChinaSchool of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaSchool of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDoxorubicin (DOX) is a highly effective chemotherapeutic drug, but its long-term use can cause cardiotoxicity and drug resistance. Accumulating evidence demonstrates that p53 is directly involved in DOX toxicity and resistance. One of the primary causes for DOX resistance is the mutation or inactivation of p53. Moreover, because the non-specific activation of p53 caused by DOX can kill non-cancerous cells, p53 is a popular target for reducing toxicity. However, the reduction in DOX-induced cardiotoxicity (DIC) via p53 suppression is often at odds with the antitumor advantages of p53 reactivation. Therefore, in order to increase the effectiveness of DOX, there is an urgent need to explore p53-targeted anticancer strategies owing to the complex regulatory network and polymorphisms of the p53 gene. In this review, we summarize the role and potential mechanisms of p53 in DIC and resistance. Furthermore, we focus on the advances and challenges in applying dietary nutrients, natural products, and other pharmacological strategies to overcome DOX-induced chemoresistance and cardiotoxicity. Lastly, we present potential therapeutic strategies to address key issues in order to provide new ideas for increasing the clinical use of DOX and improving its anticancer benefits.https://www.mdpi.com/2072-6643/15/10/2259p53DOX-induced cardiotoxicityDOX resistancedietary nutrientsnatural products |
spellingShingle | Yuanfang Guo Yufeng Tang Guangping Lu Junlian Gu p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act Nutrients p53 DOX-induced cardiotoxicity DOX resistance dietary nutrients natural products |
title | p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act |
title_full | p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act |
title_fullStr | p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act |
title_full_unstemmed | p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act |
title_short | p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act |
title_sort | p53 at the crossroads between doxorubicin induced cardiotoxicity and resistance a nutritional balancing act |
topic | p53 DOX-induced cardiotoxicity DOX resistance dietary nutrients natural products |
url | https://www.mdpi.com/2072-6643/15/10/2259 |
work_keys_str_mv | AT yuanfangguo p53atthecrossroadsbetweendoxorubicininducedcardiotoxicityandresistanceanutritionalbalancingact AT yufengtang p53atthecrossroadsbetweendoxorubicininducedcardiotoxicityandresistanceanutritionalbalancingact AT guangpinglu p53atthecrossroadsbetweendoxorubicininducedcardiotoxicityandresistanceanutritionalbalancingact AT junliangu p53atthecrossroadsbetweendoxorubicininducedcardiotoxicityandresistanceanutritionalbalancingact |